Ditchcarbon
  • Contact
  1. Organizations
  2. Nautilus Biotech S.A.
Public Profile
Pharmaceutical Preparation Manufacturing
FR
updated a month ago

Nautilus Biotech S.A. Sustainability Profile

Company website

Nautilus Biotech S.A., headquartered in France, is a pioneering company in the biotechnology sector, specialising in the development of innovative protein-based therapeutics. Founded in 2015, Nautilus has rapidly established itself as a leader in the biopharmaceutical industry, focusing on advanced drug discovery and development processes that leverage cutting-edge technologies. With a strong presence in Europe and expanding operations globally, Nautilus Biotech is renowned for its unique approach to protein engineering, which enhances the efficacy and safety of therapeutic proteins. The company’s core offerings include bespoke protein design and optimisation services, setting it apart in a competitive market. Nautilus has achieved significant milestones, including strategic partnerships and successful product launches, solidifying its position as a key player in the biotechnology landscape.

DitchCarbon Score

How does Nautilus Biotech S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

26

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Nautilus Biotech S.A.'s score of 26 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.

46%

Let us know if this data was useful to you

Nautilus Biotech S.A.'s reported carbon emissions

Nautilus Biotech S.A., headquartered in France, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and commitments suggests that Nautilus Biotech S.A. may still be in the early stages of developing its climate strategy or reporting framework. As the biotechnology industry increasingly prioritises sustainability, it is essential for companies like Nautilus Biotech S.A. to establish clear climate commitments and reduction targets to align with global efforts to mitigate climate change. Without specific emissions data or targets, the company may face challenges in demonstrating its environmental responsibility and commitment to reducing its carbon footprint in the future.

How Carbon Intensive is Nautilus Biotech S.A.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Nautilus Biotech S.A.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Nautilus Biotech S.A.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Nautilus Biotech S.A. is in FR, which has a very low grid carbon intensity relative to other regions.

Nautilus Biotech S.A.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Nautilus Biotech S.A. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Nautilus Biotech S.A.'s Emissions with Industry Peers

Bioverativ Therapeutics Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Daewoong Pharmaceutical

IN
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Novartis

CH
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

OPKO Biologics

IL
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Biogen

US
•
Pharmaceutical Preparation Manufacturing
Updated about 6 hours ago

Avadel Pharmaceuticals plc

IE
•
Pharmaceutical Preparation Manufacturing
Updated 2 months ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy